

# Maria Teresa Melucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3198416/publications.pdf>

Version: 2024-02-01

38  
papers

2,333  
citations

331670

21  
h-index

315739

38  
g-index

38  
all docs

38  
docs citations

38  
times ranked

4220  
citing authors

#	ARTICLE	IF	CITATIONS
1	The immune score as a new possible approach for the classification of cancer. <i>Journal of Translational Medicine</i> , 2012, 10, 1.	4.4	656
2	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28780.	4.6	318
3	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	4.2	230
4	Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. <i>Journal of Clinical Oncology</i> , 2005, 23, 7660-7668.	1.6	218
5	Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression. <i>Journal of Clinical Oncology</i> , 1999, 17, 304-304.	1.6	109
6	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-PCR Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2003, 21, 767-773.	1.6	91
7	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. <i>Frontiers in Oncology</i> , 2015, 5, 183.	2.8	80
8	Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. <i>British Journal of Dermatology</i> , 2000, 142, 893-898.	1.5	60
9	BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 286-292.	1.6	55
10	Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. <i>Melanoma Research</i> , 2005, 15, 235-244.	1.2	50
11	Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. <i>British Journal of Cancer</i> , 2000, 83, 1707-1714.	6.4	40
12	Unexpected Distribution of <i>CDKN2A</i> , <i>CKIT</i> , and <i>BRAF</i> Mutations among Southern Italian Patients with Sinonasal Melanoma. <i>Dermatology</i> , 2013, 226, 279-284.	2.1	36
13	Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. <i>Melanoma Research</i> , 2003, 13, 167-170.	1.2	35
14	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. <i>Oncolmmunology</i> , 2017, 6, e1283462.	4.6	34
15	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 325-332.	1.2	32
16	NEMO-binding domain peptide inhibits proliferation of human melanoma cells. <i>Cancer Letters</i> , 2009, 274, 331-336.	7.2	30
17	The immune-related role of BRAF in melanoma. <i>Molecular Oncology</i> , 2015, 9, 93-104.	4.6	28
18	Issues affecting molecular staging in the management of patients with melanoma. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 1052-1068.	3.6	27

#	ARTICLE	IF	CITATIONS
19	Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma. <i>Melanoma Research</i> , 1998, 8, 529-538.	1.2	25
20	Phenotype characterization of human melanoma cells resistant to dabrafenib. <i>Oncology Reports</i> , 2017, 38, 2741-2751.	2.6	22
21	Cisplatin, dacarbazine, and fotemustine plus interferon $\hat{\pm}$ in patients with advanced malignant melanoma. <i>Cancer</i> , 2000, 89, 2630-2636.	4.1	21
22	Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. <i>Oncology Reports</i> , 2011, 25, 1495-502.	2.6	19
23	Clinical Significance of PCR-Positive mRNA Markers in Peripheral Blood and Regional Nodes of Malignant Melanoma Patients. <i>Recent Results in Cancer Research</i> , 2001, 158, 200-203.	1.8	19
24	Molecular Classification of Patients With Malignant Melanoma for New Therapeutic Strategies. <i>Journal of Clinical Oncology</i> , 2007, 25, e20-e21.	1.6	13
25	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1917-1920.	0.7	13
26	Mutation analysis of candidate genes in melanoma-prone families. <i>Melanoma Research</i> , 2003, 13, 571-579.	1.2	11
27	Adjuvant treatment of malignant melanoma: Where are we?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 45-52.	4.4	10
28	Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. <i>Annals of Oncology</i> , 2008, 19, 2092-2093.	1.2	10
29	Adjuvant therapy of cutaneous melanoma. <i>Lancet, The</i> , 1999, 353, 328.	13.7	8
30	Mutations in ERBB4 May Have a Minor Role in Melanoma Pathogenesis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1685-1687.	0.7	8
31	The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients. <i>Annals of Oncology</i> , 2010, 21, 1379-1380.	1.2	6
32	Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment. <i>Annals of Oncology</i> , 2000, 11, 1504.	1.2	4
33	Adjuvant therapy of melanoma: what's new?. <i>Melanoma Research</i> , 2002, 12, 293-296.	1.2	4
34	Circulating melanoma-associated markers detected by RT-PCR in patients with classic Kaposiâ€™s sarcoma. <i>Annals of Oncology</i> , 2000, 11, 635-636.	1.2	3
35	Epidemiological and genetic factors underlying melanoma development in Italy. <i>Melanoma Management</i> , 2015, 2, 149-163.	0.5	3
36	Low doses interferon- $\hat{\pm}$ in the treatment of high-risk cutaneous melanoma. <i>Annals of Oncology</i> , 2000, 11, 487-490.	1.2	2

#	ARTICLE	IF	CITATIONS
37	What is changing in the adjuvant treatment of melanoma?. <i>Oncotarget</i> , 2017, 8, 110735-110736.	1.8	2
38	Mobile hospital rooms to fight melanoma. <i>Melanoma Research</i> , 2001, 11, 83-84.	1.2	1